Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05644990
Other study ID # 22-IGS06-36
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 1, 2022
Est. completion date September 1, 2025

Study information

Verified date December 2022
Source Charles University, Czech Republic
Contact Lucie Cíchová, MD
Phone +420728781647
Email lucie.cichova@protonmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Our prospective observational study focuses on the rapid detection of etiologic agents of pyogenic spondylodiscitis and infective endocarditis using the T2 Bacteria Panel (T2Biosystems). This diagnostic method combines polymerase chain reaction (PCR) and T2 magnetic resonance for detection of bacterial DNA from whole blood samples. It detects six pathogens known by the acronym ESKAPE (E. coli, S. aureus, K. pneumoniae, A. baumannii, P. aeruginosa, and E. faecium). In recent years, similar studies using the Bacteria Panel and Candida Panel have been performed in patients with bloodstream infections, leaving us with optimistic results.The aim of this study is to verify whether T2B can identify the etiologic agents of localized infections, specifically spondylodiscitis and endocarditis, with better sensitivity and specificity and shorter time to result compared to conventional diagnostics from blood culture. Rapid detection of pathogen may reduce time to targeted pathogen-specific antibiotic therapy and subsequently improve outcomes, shorten the treatment and contribute to slowing the development of antibiotic resistance.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date September 1, 2025
Est. primary completion date September 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Diagnosis of spondylodiscitis or/and facet joint infection or/and sacroileitis - Diagnosis of infective endocarditis - Antibiotic treatment not received or not longer than 24 hours - Ability to give informed consent Exclusion Criteria: - Spine infection or/and endocarditis not confirmed - Antibiotic treatment longer than 24 hours - Inability to give informed consent

Study Design


Locations

Country Name City State
Czechia University Hospital Bulovka Prague

Sponsors (3)

Lead Sponsor Collaborator
Charles University, Czech Republic Bulovka Hospital, University Hospital, Motol

Country where clinical trial is conducted

Czechia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sensitivity and Specificity of the T2 Bacteria Panel Sensitivity and specificity of the T2 Bacteria Panel for ESKAPE pathogens direct detection in patients investigated for suspected pyogenic vertebral infection and/or infective endocarditis, compared with conventional blood culture and/or other relevant biological samples culture . 3 years
Primary Expected treatment outcomes in patients diagnosed by T2 Bacteria Panel T2 Bacteria Panel is expected to shorten the time to result compared to conventional methods. Rapid detection of the bacteria followed by early pathogen-specific antibiotic therapy should improve the outcomes of patients with spondylodiscitis and infective endocarditis, e.g. mortality, morbidity and length of treatment. 4 years
Secondary Diagnostic utility of T2 Bacteria Panel in other localized infections Patients with other localized infections (other than spine or endocardium infections) who were tested with T2 Bacteria Panel before their diagnosis was assessed, will be excluded from the study. They will be separately evaluated to find out if T2MR diagnostics is useful also in other localised infections (besides of spine infection and endocarditis). 4 years
See also
  Status Clinical Trial Phase
Terminated NCT00401960 - Daptomycin as an Adjuvant Agent in the Treatment of Enterococcal Native Valve Endocarditis. Phase 4
Terminated NCT00695903 - Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia Phase 2
Recruiting NCT04840225 - Anemia in Patients With Endocarditis
Completed NCT00524212 - How to Improve Diagnosis in Infective Endocarditis N/A
Completed NCT03048643 - Combining Opioid Addiction Treatment Services With CARe for Infectious Endocarditis N/A
Completed NCT00144885 - IMAGE-Endocarditis: Resonance Magnetic Imaging at the Acute Phase of Endocarditis N/A
Completed NCT03306225 - Characterization of Endocarditis to Streptococci and Impact of the CMI on the Future of the Patients
Active, not recruiting NCT05522764 - Predictors of Infective Endocarditis Among Patients Managed for Staphylococcus Aureus Bacteremia, Particularly Staphylococcus Aureus Bacteriuria, and Time to Blood Culture Positivity
Terminated NCT04222257 - Short-course Antibiotic Treatment in Gram-positive Cocci Infective Endocarditis Phase 4
Not yet recruiting NCT05152225 - Neurological Complication of Infective Endocarditis: A Prospective Multi-site Cohort Study
Not yet recruiting NCT05613933 - Effectiveness of Antibiotic Prophylaxis of Infective Endocarditis for Invasive Dental Procedures in Patients With Prosthetic Heart Valves and/or History of Infective Endocarditis N/A
Recruiting NCT02979951 - Fosfomycin i.v. for Treatment of Severely Infected Patients
Active, not recruiting NCT06434012 - Barts Endocarditis Research Registry
Recruiting NCT06250985 - New Treatment of Cardiac Device Infections; Immediate Reimplantation After Removal of Infected System Phase 3